心脏代谢风险因素纵向变化与MASLD成人肝硬度变化相关
本研究基于NASH CRN前瞻性队列中1417例经活检证实的MASLD成人,分析心脏代谢风险因素(CMRF)年变化与肝硬度测量(LSM)、受控衰减参数(CAP)年变化的关系。结果显示CMRF恶化与LSM恶化相关,CMRF改善与LSM改善相关,CAP也呈类似关联。
要点
- CMRF恶化(除甘油三酯和HDL外)与LSM恶化相关。
- CMRF改善与LSM改善相关,体重和血糖变化关联显著。
- CAP变化与CMRF变化呈类似关联。
核心结论
- 心脏代谢风险因素的年度变化与LSM、CAP及肝脏组织学的临床相关变化有关。
研究设计与样本
- NASH CRN前瞻性研究,纳入1417例经活检证实MASLD且至少两次VCTE检查间隔≥1年的成人。
- 采用调整的混合效应多项logistic回归比较CMRF年变化与LSM、CAP年变化。
主要发现
- 所有CMRF(除甘油三酯和HDL外)年度恶化与LSM恶化相关:HbA1c每升高1%风险增加17%,体重每增加5%风险增加24%。
- 所有CMRF改善与LSM改善相关:HbA1c每降低1%改善机会增加32%,体重每降低5%改善机会增加27%。
- CAP变化也观察到与CMRF变化类似的关联。
关键数值与推荐
- 主要结局为LSM变化≥25%(对照为无变化或<25%),次要结局为CAP变化≥30%及组织学分级变化。
临床怎么用
- 治疗代谢合并症(尤其体重、血压和糖耐量异常)可能影响MASLD肝脏健康轨迹。
- 可为指南制定和临床医生提供有意义的治疗目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by cardiometabolic risk factors (CMRFs). Treatment of CMRFs is the cornerstone of MASLD management, yet other than weight loss, the association between changes in CMRFs and changes in liver-related measures is not defined. This study aimed to characterize these longitudinal associations using non-invasive measurements of hepatic fibrosis and steatosis. METHODS: Adult participants from the NASH CRN prospective study with biopsy-proven MASLD and at least two sequential vibration-controlled transient elastography (VCTE) exams (≥1 year apart) were included. Annual changes in CMRF parameters were compared against annual changes in liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) using adjusted mixed-effects multinomial logistic regression. The primary outcome was LSM change ≥25% (compared to a reference group of no change, or <25% LSM change), while secondary outcomes were CAP change ≥30% and changes in histologic grading of steatohepatitis or fibrosis. RESULTS: A total of 1,417 participants were included (mean age 52 years, 38% male, 82% Caucasian). Annual worsening in all CMRFs (except triglycerides and HDL) was associated with LSM worsening (17% greater risk per 1% increase in hemoglobin A1c; 24% greater risk per 5% increase in weight). Improvements in all CMRFs were associated with LSM improvement (32% greater chance per 1% decrease in hemoglobin A1c; 27% greater chance per 5% decrease in weight). Similar associations were observed for changes in CAP. CONCLUSIONS: Annual changes in CMRFs were associated with clinically relevant changes in LSM, CAP, and liver histology. These findings suggest that treatment of metabolic comorbidities is associated with the trajectory of MASLD. IMPACT AND IMPLICATIONS: Guideline-directed treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) is focused on optimal treatment of cardiometabolic comorbidities, but there is limited evidence on the association between outcomes of this treatment and changes in markers of liver health. The results of this study demonstrate that longitudinal changes in these cardiometabolic parameters, particularly those associated with body weight, blood pressure, and glucose intolerance, are associated with both increases and decreases in liver stiffness measurements that represent clinically meaningful changes in liver health. These results are broadly relevant to the care of individuals with MASLD, as these results can provide meaningful treatment targets for guideline development and treating clinicians, as well as provide feasible goals for impacted individuals with MASLD.
引用
- Dukewich M, Wilson LA, Dodge JL, et al. Longitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD. J Hepatol. 2026. PMID: 41687818. doi:10.1016/j.jhep.2026.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。